Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
about
Multigene assays and molecular markers in breast cancer: systematic review of health economic analysesThe Nuremberg Code subverts human health and safety by requiring animal modelingCost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in GermanyTowards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatmentRecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerPredictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis.Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.Genomic testing and therapies for breast cancer in clinical practice.US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?Review of the clinical studies using the 21-gene assay.Impact of multigene assays in early stage breast cancer.The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyGene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancerCost-utility analyses of drug therapies in breast cancer: a systematic review.Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of careUnderutilization of gene expression profiling for early-stage breast cancer in CaliforniaRacial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectivesAdoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.Economic evaluation of targeted cancer interventions: critical review and recommendations.Citizens' perspectives on personalized medicine: a qualitative public deliberation study.Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapyRecommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
P2860
Q26825362-948B2B71-EA31-468A-AA16-454DA65604A6Q26866469-3C81FC2C-0D00-4978-9DE5-13FE0E428CE5Q28072203-7029E832-8023-4968-B3EB-042E45702B55Q30252422-6448977E-66DD-4F2F-B1AC-47254D9DB044Q30378787-46B791F6-E600-45FD-8669-8E25EE1DC874Q31101528-564BD30D-0C82-4EFB-951C-C0C1EEAEFC25Q33763903-8937737A-8991-4A13-9BBE-E1BFB5EEF247Q33966102-EF0F8C86-6264-43A6-ACCD-C9BDCE0C1792Q34022200-5FA9C353-91D9-49A0-8883-445A89C4F72DQ34171119-93BD6B2A-B34E-462E-916A-D2A2E0334B1FQ34338152-5F6AE63F-8BFB-456A-911F-5CC936DA6B75Q34341066-EAC35955-FB14-4E23-8E91-CA25DBDBAF79Q34416758-7836ACC2-5643-44B2-BE06-07C4D1284FFAQ34431985-8E1C89FF-FA95-4DB9-900A-77AD9CA29529Q34638067-165EC972-EB8C-49FC-94C9-D13A125CEC58Q34974164-61B105EC-D50D-482B-91AC-3206EB149F6BQ34974208-7530D12B-7DED-47FB-927A-B0479754248FQ35146930-473329D0-8142-4C9F-B50B-61FB2EEC744EQ35584053-40E6F39D-51BB-400F-B075-FD357868372BQ35599759-B0EF410F-276F-4CB9-83B1-B2DC4CB494A2Q35599773-1E5BA269-2FD9-4775-8764-33A8BAB4D3DBQ35915708-6B856A9B-102B-4760-B9B6-1B9CF3F0E9E2Q36055953-70422C69-E0FF-4509-BD01-32CA255638B6Q36097503-75418CCE-1183-4EA7-982E-9FFF79532DCBQ36116276-A315BE6F-EAB1-4750-A783-26CD91AB6398Q36253744-B4516CCB-5730-43EE-98D9-A8F05B74165BQ36339076-D8025A73-C987-4816-B473-DADA45157263Q36424052-71F89408-13B8-47D2-8D5A-1C7D94843D70Q36615770-E37046DA-9318-4393-A2A2-93B5256E2D79Q36661690-D77F2AE8-371C-48ED-8AE3-AB902A521423Q36913542-AF6459D9-66ED-46E2-9114-EC34B4EEA4C4Q36914381-0205905F-76E4-4277-BE51-98FBD3C130AEQ36924703-41A7D6F8-D129-4EE8-B5DD-4DFE89EACE88Q37095310-5DE21D35-9799-4042-8845-91AEF98ABD7BQ37131845-F7A08CE3-6FD8-486F-AEFC-A0380AD96ADDQ37151779-FA5FB450-5973-4373-9F6D-B4B1829C19BFQ37173971-6FF689BE-D98B-4B44-8B43-D9D93EF4EE4EQ37235111-260134F3-E203-471F-8393-16024F92973BQ37342385-5D00714C-BB3E-4D9E-8327-38638E09B107Q37345983-041BF16F-3D42-4574-966A-B94557D9BB69
P2860
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@ast
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@en
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@nl
type
label
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@ast
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@en
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@nl
prefLabel
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@ast
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@en
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@nl
P2093
P356
P1433
P1476
Impact of a 21-gene RT-PCR ass ...... predictive validation studies.
@en
P2093
Gary H Lyman
John Hornberger
Leon E Cosler
Nicole M Kuderer
P2860
P304
P356
10.1002/CNCR.22506
P407
P577
2007-03-01T00:00:00Z